Phase II Study of Five-Day Continuous Infusion of Vinblastine in Patients With Metastatic Renal-Cell Carcinoma
- 1 June 1987
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 10 (3) , 231-233
- https://doi.org/10.1097/00000421-198706000-00012
Abstract
Vinblastine 5-day continuous infusion in metastatic renal-cell carcinoma was evaluated in a Phase II trial. The dosage varied from 1.4 to 1.6 mg/m2/day every 3 weeks according to previous treatment and performance status (PS). From September 1983 to January 1986, 25 consecutive patients entered the study; 21 were evaluable for response and 23 were evaluable for toxicity. The median number of cycles administered was three (range, one to six). One complete response (liver) lasting 5 months, one partial response (lung) lasting 3 months, 12 cases of stable disease, and seven progressions were noted. Toxicity (WHO criteria) was relevant and mainly hematological: one treatment-related death occurred. Vinblastine continuous infusion did not demonstrate significant antineoplastic activity against metastatic renal-cell carcinoma.This publication has 4 references indexed in Scilit:
- Five-day continuous-infusion vinblastine in the treatment of breast cancerCancer, 1985
- CLINICAL PHARMACOKINETICS OF VINBLASTINE BY CONTINUOUS INTRAVENOUS-INFUSION1983
- VINBLASTINE GIVEN AS A CONTINUOUS 5-DAY INFUSION IN THE TREATMENT OF REFRACTORY ADVANCED BREAST-CANCER1980
- Renal Cell Carcinoma: Natural History and Results of TreatmentJournal of Urology, 1978